GlassScriptPhysician profile
Blake Daniel Koceja
NPI 1205585874
$7,892.01
in general payments reported to CMS, 2019-2025
54 companies · $3,187 in 2025
The $3,187 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,005 · 2024: $3,700 · 2025: $3,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,334 · Education: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,334.07 |
| Education | $557.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $694.77 | 2023-2025 | |
| Incyte Corporation | $519.24 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $455.48 | 2023-2025 | Rybrevant, Erleada, Carvykti |
| Merck Sharp & Dohme LLC | $382.18 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $344.87 | 2023-2025 | Imfinzi, Calquence, Enhertu |
| Abbvie INC. | $334.65 | 2024-2025 | |
| Astellas Pharma US INC | $324.38 | 2023-2024 | Padcev, Xtandi, Xospata |
| Glaxosmithkline, LLC. | $273.27 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Sobi, INC | $260.10 | 2024-2025 | |
| Eisai INC. | $230.04 | 2024-2025 | |
| Genentech USA, INC. | $229.52 | 2023-2025 | Venclexta, Polivy, Tecentriq |
| Pharmacosmos Therapeutics INC. | $224.62 | 2023-2025 | Monoferric, Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $213.45 | 2023-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Pfizer INC. | $207.20 | 2023-2024 | |
| Taiho Oncology, INC. | $204.35 | 2024-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $202.49 | 2023-2025 | Reblozyl, Opdivo |
| Lilly USA, LLC | $194.91 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Jazz Pharmaceuticals INC. | $161.33 | 2023-2025 | |
| Daiichi Sankyo INC. | $149.81 | 2023-2025 | Enhertu, Datroway |
| Adaptive Biotechnologies Corporation | $144.70 | 2024-2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $141.97 | 2025 | |
| Pharmaessentia USA Corporation | $141.37 | 2024-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $137.89 | 2024-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $132.08 | 2023-2025 | |
| Acrotech Biopharma INC. | $126.07 | 2023-2025 | Beleodaq |
| Gilead Sciences, INC. | $102.63 | 2023-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.00 | 2024-2025 | Gilotrif |
| Adc Therapeutics America, INC. | $99.08 | 2024-2025 | |
| Genmab U.S., INC. | $97.94 | 2023-2024 | Tivdak, Epkinly |
| Array Biopharma INC | $89.26 | 2025 | Braftovi, Mektovi, Tukysa |
| Karyopharm Therapeutics INC. | $87.81 | 2023-2025 | Xpovio |
| Azurity Pharmaceuticals, INC. | $86.17 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $75.78 | 2024 | Panhematin |
| Alexion Pharmaceuticals, INC. | $66.48 | 2024-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $52.23 | 2023-2025 | Qinlock, Romvimza |
| Kyowa Kirin, INC. | $51.19 | 2023-2025 | Poteligeo |
| Legend Biotech USA INC. | $47.99 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $47.35 | 2024 | Onivyde, Somatuline Depot |
| Celgene Corporation | $44.48 | 2024 | Pomalyst, Reblozyl |
| Beigene USA, INC. | $43.64 | 2024 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $43.43 | 2025 | Rolvedon |
| Amneal Pharmaceuticals LLC | $42.99 | 2024 | Avastin |
| Seagen INC. | $35.33 | 2023 | Padcev, Adcetris |
| Beone Medicines USA, INC. | $32.91 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $28.67 | 2025 | Quzyttir |
| Sandoz INC. | $26.78 | 2025 | Cyclophosphamide |
| Geron Corporation | $24.88 | 2025 | Rytelo |
| Coherus Oncology, INC. | $22.37 | 2023 | |
| Novocure INC. | $21.47 | 2024 | Optune Lua (Novottf-200t) |
| Rigel Pharmaceuticals, INC. | $20.38 | 2024 | Tavalisse, Rezlidhia |
| Fennec Pharmaceuticals, INC. | $19.38 | 2024 | Pedmark |
| Puma Biotechnology, INC. | $18.03 | 2025 | |
| Stemline Therapeutics INC. | $17.41 | 2025 | Elzonris |
| Immunocore Limited | $15.21 | 2024 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Koceja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.